Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database

Alfonso J. Tafur1 Harry Fuentes2 Joseph A. Caprini1 Agustina Rivas3 F. Uresandi4 Rita Duce5
Raquel Lopez-Reyes6 Adriana Visona7 Adel Merah8 Manuel Monreal9

1NorthShore University HealthSystem, Evanston, Illinois, United States
2John Stroger Cook County Hospital, Chicago, Illinois, United States
3Hospital Universitario Araba, Álava, Spain
4Hospital de Cruces, Barakaldo, Vizcaya, Spain
5Ospedale Galliera, Genova, Italy
6Hospital Universitari i Politècnic La Fe, Valencia, Spain
7Ospedale Castelfranco Veneto, Castelfranco Veneto, Italy
8Université Jean-Monnet, Service de Medecine Vasculaire et Therapeutique, CHU de Saint Etienne, Saint-Etienne, France
9Hospital Universitario Germans Trias i Pujol de Badalona, Universidad Católica de Murcia, Barcelona, Spain

Address for correspondence Dr. Alfonso J. Tafur, Department of Medicine, Vascular Medicine, NorthShore University HealthSystem, 2650 Ridge Avenue, Evanston, IL 60201, United States (e-mail: atafur@northshore.org).

TH Open 2018;2:e158–e166. 

Abstract

Cancer-associated thrombosis (CT) carries a high, heterogeneous, and poorly predicted likelihood of mortality. Thus, we aimed to define predictors of 30-day mortality in 10,025 patients with CT. In a randomly selected derivation cohort, we used recursive partitioning analysis to detect variables that select for a risk of mortality within 30 days. In a validation cohort, we evaluated our results using Cochran–Armitage test. The most common types of cancer were lung (16%), breast (14%), and colorectal (14%); median age was 69 years (range, 14–101); most had metastatic disease (63%); 13% of patients died within 30 days. In the derivation cohort (n = 6,660), a white blood cell (WBC) count in the highest quartile predicted early mortality (odds ratio, 7.8; 95% confidence interval [CI], 4.6–13.1); and the presence of metastatic disease, pulmonary embolism (PE), and immobility defined the risk of those with normal WBC count. We defined death risk according four sequential questions: (1) Does the patient have an elevated WBC count? (Yes, group D). (2) If no, does the patient have metastasis? (No, group A). (3) If yes, is the patient immobile? (Yes, group D). (4) If no, does the patient have a PE? (Yes, group C; no, group B). In the validation cohort (n = 3,365), the 30-day risk of death was 2.9% in group A (95% CI, 1.9–4.3), compared with 25% in group D (95% CI, 22.5–27.5), and there was a rate escalation between groups (p for trend < 0.01). In conclusion, with four sequential questions, the risk of death in CT can be easily stratified. An elevated WBC count at baseline predicted 30-day mortality better than metastases, PE, or immobility.

Keywords
► mortality
► cancer
► venous thromboembolism

received December 19, 2017
accepted after revision March 13, 2018
Introduction

Cancer-associated thrombosis (CT) is a frequent, potentially preventable complication of cancer treatment, which is independently associated with higher rate of mortality.\(^1\,2\) Primary thromboprophylaxis strategies using low-molecular-weight heparin (LMWH) have been tested in randomized trials and led to a defined reduction in the likelihood of venous thromboembolism (VTE), without a clear effect in mortality.\(^3\,4\) There is a limited understanding of which patients with CT have the highest likelihood of postthrombosis mortality. With the advent of alternative methods of anticoagulation with diverse bleeding and efficacy profile,\(^5\,6\) there is a need to better allocate preventive and therapeutic strategies.

The currently available mortality prediction tools for patients with VTE have performance limitations among patients with CT. Thus, the Pulmonary Embolism Severity Index (PESI) is a validated score to predict pulmonary embolism (PE)–related mortality. However, the score is only valid for patients with PE; the performance in patients with cancer is modest (area under the curve [AUC], 0.7), and cancer as a single variable is very heavily weighted in the score, potentially limiting dispersion of the model.\(^7\,8\) In contrast, POMPE-C was derived from a population with PE and cancer; it has a better performance in external validation (AUC, 0.8), but is only valid for patients with PE; the performance in patients without PE on presentation is 0.5.\(^9\,10\) These scores have a segmented and limited approach to mortality prediction in CT: the scores assume that only patients with PE will have a high mortality. Fatal PE alone does not explain the mortality in the registries.\(^11\) Therefore, patients without PE on presentation have a high mortality risk that is not stratified with the current tools.

We decided to analyze the RIETE database to identify the group of patients with cancer and thrombosis with the highest risk of death within 30 days of a thrombosis.

Methods

Inclusion Criteria and Baseline Variables

We included patients with CT from the RIETE database. RIETE (ClinicalTrials.gov identifier: NCT02832245) is a multicenter, ongoing, global observational registry. Since 2001, we have used RIETE to evaluate outcomes after acute venous thrombosis. Consecutive patients with acute deep vein thrombosis (DVT) or PE confirmed by objective testing (compression ultrasound or contrast venography for DVT; helical computed tomography or ventilation perfusion scan or angiography for PE) were included. Patients with incidental, or arm, or visceral thrombosis were not excluded. Only the patients with adjudicated follow-up data for at least 3 months are considered valid entries in the registry. Active cancer was defined in those patients who have been diagnosed with cancer less than 3 months before VTE, patients with metastatic disease, or those receiving therapy at the time of diagnosis. Skin malignancies including melanoma were excluded.

Cancer-related variables included cancer type, metastatic disease, chemotherapy, hormonal therapy, and radiation therapy at diagnosis. Immobility was defined as bed rest for more than 4 days in the last 2 months. PE on presentation and bilateral versus unilateral DVT were also documented. Recent surgery was recorded if there was a major intervention in the 2 months preceding VTE. We obtained laboratory values including platelet count, hemoglobin, white blood cell (WBC) count, and creatinine at diagnosis. Demographics and comorbidities known at the time of VTE diagnosis were also recorded and included history of cerebral ischemia, symptomatic peripheral artery disease, prior myocardial infarction, hypertension, chronic kidney disease, diabetes, and smoking history. Data were collected via electronic case form on all participating sites (see Appendix). The data quality was regularly monitored for quality. All patients (or their relatives) provided written or oral consent for participation in the registry, in accordance with local ethics committee requirements.

Statistical Analysis

We divided 2:1 the database between a derivation and a validation cohort using simple random selection. To demonstrate homogeneity of the derivation and the validation cohorts, we used Student’s t-test and the Mann–Whitney U test for continuous variables and chi-squared or Fisher’s exact test for categorical variables.

We categorized continuous variables in quartiles unless otherwise suggested in literature. To identify risk groups in the derivation cohort, we used a recursive partitioning and amalgamation method using a graphical approach to prune unnecessary splits.\(^15\,16\) We chose this strategy predominantly as a pragmatic approach to minimize the effect of multiple statistical interactions in this population, a “small n large p” problem.\(^17\) This is illustrated by over 1,000 potential combinations by analyzing only basic interactions in this database. In addition, recursive partitioning has been successfully used in multiple cancer and vascular thrombosis cohorts to define risk groups.\(^18\,19\) Finally, recursive partitioning is a valid alternative to Cox’s proportional hazard for the analysis that obviates the assumptions of a constant relative risk through the follow-up.\(^20\) After the selection of the groups of risk, we amalgamated two populations with the smallest dissimilarity.\(^22\)

The treatment received by the patients was not included in the models. We chose not to do so because of multiple reasons: during the first 30 days, the initial use of LMWH is a globally accepted standard of care; our goal was to define the death risk with descriptors available at diagnosis; and given that the treatment choices including filter placement or intensity of anticoagulant agents in the database reflect
the real-life management of the disease that, in the absence of any, were not guided by a valid CT-specific mortality stratification score. There was no imputation of missing values.

We tested the findings in the validation cohort calculating the risk of death in each group and measured p-values for trend using a Cochran–Armitage test. To explore how robust our findings were, we isolated the analysis into predefined denominators: lung cancer, gastrointestinal malignancies, breast cancer, males. In addition, adjusted odds ratios (ORs) were calculated by controlling for relevant covariates by means of multiple logistic regression analysis. Accounting for multiple comparisons, we used a Bonferroni correction to a p < 0.002 as significant difference. Statistical analysis was done with IBM SPSS statistical program version 23 (Armonk, New York, United States).

Results

We studied a total 10,025 patients with CT. The most common type of cancer was lung with 16.4% (n = 1,658), followed by breast (n = 1,418) and colorectal (n = 1,392) with 14%. The median age was 69 years (range, 14–101 years), and most had metastatic disease (n = 6,361, 63%). The derivation cohorts included 6,660 patients and there were no significant differences compared with the validation cohort (n = 3,365) (Table 1). Most of the patients in the derivation (n = 6,153, 92.4%) and validation cohorts (n = 3,089, 91.8%) received LMWH initially. There were 1,276 (12.6%) patients who died within the first month, evenly distributed between the derivation and validation cohorts.

In the recursive partitioning analysis of the derivation cohort, an increased WBC count level in the highest quartile was a strong predictor of early mortality (OR, 7.8, 95% confidence interval [CI], 4.6–13.1). In the recursive partition analysis, the presences of PE, metastatic disease, or recent immobility were the additional variables that created the regression tree for selection of the groups at risk. Increased WBC count was a better discriminator of death risk than the combination of metastatic disease, immobility, and PE (Fig. 1). After controlling for potential confounders including chemotherapy, metastatic disease, PE at baseline, and age, the adjusted OR was 3.3 (95% CI, 2.9–3.8). Patients with elevated WBC count and the subset of patients with no WBC count elevation but presence of metastases and immobility had the smallest dissimilarity in the mortality risk prediction (Fig. 1); thus, we amalgamated these groups into a single category. Therefore, the final risk groups were (Fig. 2):

- Patients with high WBC count on diagnosis; or those with metastatic disease and immobility on diagnosis (group D, highest death risk).
- If there was no elevated WBC count or immobility, those with metastasis and PE were group C (high death risk).
- Patients without elevated WBC count, PE, or recent immobility but with evidence of metastases were group B (intermediate death risk).

- Patients with normal WBC count and no metastases were group A (lower death risk), regardless of PE or immobility status.

There were 429 (12.7%) out of 3,365 patients who died within 1 month in the validation cohort. We observed again an escalation on the risk of mortality within the first month according to the risk groups. The risk of early death after CT was 2.9% in group A (95% CI, 1.9–4.3), compared with 25% in the group D (95% CI, 22.5–27.5) (Fig. 3). In the subgroup analysis, we found a significant p for trend among men (p < 0.0001), women (p < 0.0001) (not shown in the figure), and in patients with breast cancer (p < 0.0001), gastrointestinal cancer (p < 0.0001), and lung cancer (p < 0.0001) only subsets (Fig. 4).

We measured the main differences between those patients with increased WBC count and the rest of the cohort. Patients with elevated WBC count also had higher platelet count (236.00 ± 132 vs. 229.00 ± 131 x 10^9/L; p < 0.0001) and were less commonly receiving chemotherapy (47.8 vs. 63.9%; p < 0.0001), and most had metastatic disease (72.7 vs. 59.3%; p < 0.0001).

Discussion

In a very large database of patients with CT, we have defined and validated groups of patients with escalating likelihood of mortality. We propose a simplified set of questions to rapidly categorize risk groups on presentation (Fig. 2). Patients with elevated WBC count on diagnosis of CT, along with those with normal WBC count but with metastatic disease and immobility, had the highest 30-day mortality.

The reported mortality rate, demographics, and cancer type distribution in our study are consistent with that observed in recent cancer thrombosis trials.6,10,11,13 In the EPIPHANY trial, it was already noted that among patients with cancer-associated PE, there were some predictors of death that overlap with our findings.23 The authors evaluated 1,033 patients with PE and found that performance status and metastatic disease were predictors of death. Direct comparisons with our database are limited as patients with DVT only were not included. The Khorana risk assessment score, initially developed to predict CT among patients receiving chemotherapy, includes elevated WBC count within the classification.24 The Khorana score has been associated with higher likelihood of mortality in patients with cancer, but in our analysis none of the other variables within the score predicted 30-day mortality.25,26 Our findings add to a recent publication in which the value of the Khorana score as a mortality predictor in patients with CT had limited performance (AUC, 0.54; 95% CI, 0.52–0.56).27 Only 23% of the fatalities were among patients with high-risk Khorana score. In contrast, in our current study, WBC count alone selects 50% of the early fatalities.

Strengths of our research include the utilization of a very large prospectively collected database, which has allowed us to derive and validate our findings; our findings were robust, and confirmed in several subsets of patients. A prediction
Table 1 Baseline characteristics of the cohort

| Variables                      | Cohort (N = 10,025) | Validation (N = 3,365) | Derivation (N = 6,660) | p-Value |
|-------------------------------|---------------------|------------------------|-------------------------|---------|
|                               | n                   | %                      | n                       | %       | n                   | %               |         |         |
| **Patient-related variables** |                     |                        |                         |         |                     |                 |         |         |
| Age (quartiles), y            |                     |                        |                         |         |                     |                 |         |         |
| 0–59                          | 2,720               | 26.9                   | 898                     | 26.7    | 1,793               | 26.9            | 0.754   |         |
| 60–69                         | 2,636               | 26.1                   | 859                     | 25.5    | 1,754               | 26.3            |         |         |
| 70–77                         | 2,503               | 24.8                   | 851                     | 25.3    | 1,635               | 24.5            |         |         |
| > 77                          | 2,252               | 22.3                   | 757                     | 22.5    | 1,478               | 22.2            |         |         |
| Male gender                   | 5,389               | 53.3                   | 1,789                   | 53.2    | 3,554               | 53.4            | 0.851   |         |
| **BMI**                       |                     |                        |                         |         |                     |                 |         |         |
| Underweight                   | 213                 | 2.1                    | 73                      | 2.2     | 140                 | 2.1             | 0.579   |         |
| Normal                        | 2,631               | 26.0                   | 842                     | 25.0    | 1,768               | 26.5            |         |         |
| Overweight                    | 2,744               | 27.1                   | 931                     | 27.7    | 1,802               | 27.1            |         |         |
| Obese class I                 | 1,090               | 10.8                   | 362                     | 10.8    | 711                 | 10.7            |         |         |
| Obese class II                | 289                 | 2.9                    | 95                      | 2.8     | 191                 | 2.9             |         |         |
| Morbid obese                  | 146                 | 1.4                    | 41                      | 1.2     | 104                 | 1.6             |         |         |
| **Cancer variables**          |                     |                        |                         |         |                     |                 |         |         |
| Site                          |                     |                        |                         |         |                     |                 |         |         |
| Oropharynx/larynx             | 170                 | 1.7                    | 61                      | 1.8     | 109                 | 1.6             | 0.579   |         |
| Esophagus                     | 109                 | 1.1                    | 35                      | 1.0     | 74                  | 1.1             |         |         |
| Lung                          | 1,658               | 16.4                   | 569                     | 16.9    | 1,089               | 16.4            |         |         |
| Breast                        | 1,418               | 14.0                   | 484                     | 14.4    | 934                 | 14.0            |         |         |
| Stomach                       | 400                 | 4.0                    | 142                     | 4.2     | 258                 | 3.9             |         |         |
| Pancreas                      | 509                 | 5.0                    | 180                     | 5.3     | 329                 | 4.9             |         |         |
| Colorectal                    | 1,392               | 13.8                   | 462                     | 13.7    | 930                 | 14.0            |         |         |
| Ovary                         | 338                 | 3.3                    | 109                     | 3.2     | 229                 | 3.4             |         |         |
| Bladder                       | 491                 | 4.9                    | 159                     | 4.7     | 332                 | 5.0             |         |         |
| Prostate                      | 950                 | 9.4                    | 325                     | 9.7     | 625                 | 9.4             |         |         |
| Brain                         | 332                 | 3.3                    | 104                     | 3.1     | 228                 | 3.4             |         |         |
| Hematological                 | 735                 | 7.3                    | 220                     | 6.5     | 515                 | 7.7             |         |         |
| Unknown origin                | 255                 | 2.5                    | 90                      | 2.7     | 165                 | 2.5             |         |         |
| Uterus                        | 377                 | 3.7                    | 109                     | 3.2     | 268                 | 4.0             |         |         |
| Kidney                        | 168                 | 1.7                    | 52                      | 1.5     | 116                 | 1.7             |         |         |
| Others                        | 497                 | 4.9                    | 181                     | 5.4     | 316                 | 4.7             |         |         |
| HCC                           | 52                  | 0.5                    | 19                      | 0.6     | 33                  | 0.5             |         |         |
| Biliary system                | 138                 | 1.4                    | 50                      | 1.5     | 88                  | 1.3             |         |         |
| Vulva                         | 36                  | 0.4                    | 14                      | 0.4     | 22                  | 0.3             |         |         |
| Metastasis                    | 6,361               | 62.9                   | 2,139                   | 63.6    | 4,147               | 62.3            | 0.189   |         |
| **Comorbidities**             |                     |                        |                         |         |                     |                 |         |         |
| Bleeding in the past month    | 251                 | 2.5                    | 77                      | 2.3     | 171                 | 2.6             | 0.395   |         |
| Prior myocardial infarction   | 216                 | 2.1                    | 138                     | 4.1     | 272                 | 4.1             | 0.528   |         |
| Prior TIA or stroke           | 317                 | 3.1                    | 112                     | 3.3     | 203                 | 3.0             | 0.486   |         |
| PAD                           | 216                 | 2.1                    | 84                      | 2.5     | 132                 | 2.0             | 0.0129  |         |
| Current smoker                | 774                 | 7.7                    | 273                     | 8.1     | 500                 | 7.5             | 0.326   |         |

(Continued)
tool, beyond its statistical performance, will only be as clinically useful as its ease of implementation. Our methodology allows for a simplified set of questions to rapidly estimate mortality risk (►Fig. 2). Moreover, the global nature of this database allows us to represent the likelihood of early mortality after CT with real-life generalizability. There are limitations to our analysis; there was no standardization of initial anticoagulant therapy. However, most patients with CT in the RIETE database are indeed treated with LMWH initially, as it is the current standard of care.

Among patients with PE, an increased right ventricle /left ventricle ratio seen in the CT would select patients with higher mortality risk.28 We did not have access to this information; this limitation, however, is not pertinent for those patients who present without PE, and the role of the ratio in mortality prediction has not been definitively analyzed among patients with cancer. We did not have enough granular information as to explore potential medications and type of chemotherapy that could have explained our findings. The database does not uniformly contain troponin levels, which are an indicator of mortality among patients with PE.29 Although the performance status was not prospectively entered, the value of immobility reflects on the known risk of death for patients with high ECOG status. We did not analyze stage other than metastatic versus not metastatic. The analysis of stage, however, is more likely to be valuable in single cancer–type models since equal cancer stage does not correlate with death risk across cancer types.

It was intriguing that WBC results predicted such a large number of patients with death. When we defined those

### Table 1 (Continued)

| Variables | Cohort (N = 10,025) | Validation (N = 3,365) | Derivation (N = 6,660) | p-Value |
|-----------|---------------------|------------------------|------------------------|---------|
|           | n | %   | n | %   | n | %   |             |
| Diabetes  | 1,065 | 10.5 | 342 | 10.2 | 709 | 10.6 | 0.642 |
| Hypertension | 2,682 | 26.5 | 912 | 27.1 | 1,741 | 26.1 | 0.165 |
| Prior VTE | 1,247 | 12.3 | 408 | 12.1 | 835 | 12.5 | 0.554 |
| Immobility | 1,935 | 19.1 | 665 | 19.8 | 1,246 | 18.7 | 0.205 |
| Severe COPD | 43 | 0.4 | 11 | 0.3 | 32 | 0.5 | 0.266 |
| CKD | 1,039 | 10.3 | 353 | 10.5 | 678 | 10.2 | 0.773 |
| Surgery | 1,037 | 10.3 | 367 | 10.9 | 670 | 10.1 | 0.189 |
| Medications | |
| Statin | 1,134 | 11.2 | 385 | 11.4 | 733 | 11.0 | 0.335 |
| Chemotherapy | 6,050 | 59.8 | 1,991 | 59.2 | 4,006 | 60.2 | 0.217 |
| Laboratory values | |
| Hemoglobin (g/dL) | 11.79 | 2.12 | 11.75 | 1.96 | 11.82 | 2.20 | 0.384<sup>a</sup> |
| White blood cells (×1,000/mm<sup>3</sup>) | 8.80 | 5.30 | 8.42 | 4.66 | 9.11 | 5.48 | 0.343<sup>b</sup> |
| Platelets (×1,000/mm<sup>3</sup>) | 230.50 | 130.00 | 233.50 | 118.38 | 228.50 | 136.00 | 0.189<sup>b</sup> |
| Fibrinogen (mg/dL) | 551.50 | 222.50 | 555.00 | 224.00 | 549.50 | 210.50 | 0.213<sup>b</sup> |
| Total cholesterol (mg/dL) | 178.50 | 61.87 | 174.76 | 66.75 | 179.50 | 60.43 | 0.743<sup>b</sup> |
| HDL-cholesterol (mg/dL) | 41.76 | 15.17 | 41.21 | 15.50 | 42.01 | 15.06 | 0.176<sup>a</sup> |
| LDL-cholesterol (mg/dL) | 103.90 | 50.85 | 104.50 | 52.08 | 103.90 | 52.75 | 0.317<sup>b</sup> |
| Triglycerides (mg/dL) | 136.00 | 80.00 | 129.50 | 77.13 | 144.12 | 80.00 | 0.056<sup>b</sup> |
| Creatinine (mg/dL) | 0.90 | 0.44 | 0.86 | 0.45 | 0.90 | 0.42 | 0.303<sup>b</sup> |
| Outcome | |
| Death within 1 month | 1,276 | 12.6 | 429 | 12.7 | 827 | 12.4 | 0.636 |

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HCC, hepatocellular carcinoma; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; PAD, peripheral arterial disease; TIA, transient ischemic attack; VTE, venous thromboembolism.

Note: Immobility defined as ≥4 days of bed rest in the last 2 months. All p-values were calculated with chi-squared test unless otherwise specified.

<sup>a</sup>Expressed as mean and standard deviation, t-test.

<sup>b</sup>Mann–Whitney U test.
patients with elevated WBC count, patients with metastasis and chemotherapy were more likely to have an increased WBC counts; but neither of those variables had a better discriminatory power than WBC alone. It is plausible that some of them were receiving steroids, which was not a collected variable. We do not know which patients had infections detected on admission; thus, sepsis may also account for some of the results. Elevated leukocyte count has already been associated with cancer-associated mortality in prior studies, but not deeply explored in the context of CT. While chronic inflammation has been suggested as a link between mortality and malignancy, it is also associated with VTE incidence. The degree of inflammatory response is another potential explanation of the observed death rate. The likelihood of death among patients without metastasis and who are mobile and do not have PE is low. Our findings may cause one to rethink the intensity of anticoagulation in this subset of patients since they have a very high likelihood of bleeding during anticoagulation.

In conclusion, we have derived and validated a robust set of characteristics that select patients with highest likelihood of death after CT. We present our result as an easy to implement, short sequence of questions. Our findings may be considered when analyzing risk and benefits of anticoagulation therapy, and may help adjust resource allocation with the growing number of therapeutic strategies in CT.

Fig. 1  Groups at risk of early mortality after cancer-associated thrombosis in the derivation cohort. Derivation cohort death risk categories and odds of 30-day mortality. Patients with a missing variable were not carried forward in the count.

Fig. 2  Sequence of questions to define risk groups.
Fig. 3  Trends for early mortality after cancer-associated thrombosis in derivation and validation cohort. Cochran–Armitage \( p \) for trend in early mortality after CT for derivation and validation cohorts.

Fig. 4  Early mortality by groups at risk in the validation cohort of patients with cancer-associated thrombosis. (A) No metastatic disease and no elevated WBC count. (B) Metastatic disease without PE, immobility, elevated WBC count. (C) Metastasis and PE without elevated WBC count or immobility. (D) Elevated WBC count or metastatic disease with immobility in patients without elevated WBC count. GI, gastrointestinal.
Conflict of Interest
None declared.

Acknowledgments
We express our gratitude to Sanofi Spain for supporting this registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this registry. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain, which accounts for a 24.18% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data and logistic and administrative support.

References
1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122(10):1712–1723
2 Fuentes HE, Tafur AJ, Caprini JA. Cancer-associated thrombosis. Dis Mon 2016;62(05):121–158
3 Phan M, John S, Casanegra AI, et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis 2014;38(02):241–249
4 Fuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res 2017;154:28–34
5 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015;136(03):582–589
6 Raskob G, Ageno W, Cohen AT, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016;3(05):e228–e236
7 Posch F, Ay C. Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism? Eur Respir J 2017;49(01):1602225
8 Dentali F, Riva N, Turato S, et al. Pulmonary embolism severity index accurately predicts long-term mortality rate in patients hospitalized for acute pulmonary embolism. J Thromb Haemost 2013;11(12):2103–2110
9 Kline JA, Roy PM, Than MP, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool. Thromb Res 2012;129(05):e194–e199
10 Nguyen E, Caranfa JT, Lyman GH, et al. Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis. J Thromb Haemost 2018;16(02):279–292
11 Weeda ER, Caranfa JT, Zeichner SB, Coleman CI, Nguyen E, Kohn CG. External validation of generic and cancer-specific risk stratification tools in patients with pulmonary embolism and active cancer. J Natl Compr Canc Netw 2017;15(12):1476–1482
12 Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013;131(01):24–30
13 Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(02):146–153
14 Lee AYY, Kamphuisen PW, Meyer G, et al; CATCH Investigators. Ticagrelor vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314(07):677–686
15 Young SS, Ge N. Recursive partitioning analysis of complex disease pharmacogenetic studies. I. Motivation and overview. Pharmacogenomics 2005;6(01):65–75
16 Segal MR. Extending the elements of tree-structured regression. Stat Methods Med Res 1995;4(03):219–236
17 Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods 2009;14(04):323–348
18 Louie AV, Haasbeek C, Mokhles S, et al. Predicting overall survival after stereotactic ablative radiation therapy in early-stage lung cancer: development and external validation of the Amsterdam Prognostic Model. Int J Radiat Oncol Biol Phys 2015;93(01):82–90
19 Pal SK, Vuong W, Zhang W, et al. Clinical and translational assessment of VEGFR1 as a mediator of the premetastatic niche in high-risk localized prostate cancer. Mol Cancer Ther 2015;14(12):2896–2900
20 Kirkpatrick AC, Tafur AJ, Vincent AS, Dale GL, Prodan CI. Coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis. Stroke 2014;45(10):2995–3001
21 Ciampi A, Hogg SA, Kates L. Regression analysis of censored survival data with the generalized F family—an alternative to the proportional hazards model. Stat Med 1986;5(01):85–96
22 Ciampi A, Hogg SA, McKinney S, Thiffault J. RECPAM: a computer program for recursive partition and amalgamation for censored survival data and other situations frequently occurring in biostatistics. I. Methods and program features. Comput Methods Programs Biomed 1988;26(03):239–256
23 Font C, Carmona-Bayonas A, Beato C, et al; Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 2017;49(01):1600282
24 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902–4907
25 Mansfield AS, Tafur AJ. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply. J Thromb Haemost 2017;15(03):591–592
26 Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A validated risk score for venous thromboembolism is predictive of cancer progression and mortality. Oncologist 2016;21(07):861–867
27 Tafur AJ, Caprini JA, Cote L, et al; RIETE Investigators. Predictors of active cancer thromboembolic outcomes, RIETE experience of the Khorana score in cancer-associated thrombosis. Thromb Haemost 2017;117(06):1192–1198
28 Meinel FG, Nance JW Jr, Schoepf UJ, et al. Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. Am J Med 2015;128(07):747–59. e2
29 Becattini C, Agnelli G, Lankeit M, et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J 2016;48(03):780–786
30 Trujillo-Santos J, Di Micco P, Iannuzzo M, et al; RIETE Investigators. Elevated white blood cell count and outcome in cancer patients
with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100(05):905–911

31 Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010;126 (02):113–118

32 Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Obayashi K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001;92(09):2399–2405

33 Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010;30(01):5–6, 8–9

Appendix

Members of the RIETE Group: SPAIN: Adarraga MD, Aíbar MA, Alfonso M, Arcelus JL, Ballaz A, Baños P, Barba R, Barrón M, Barrón-Andrés B, Bascuñana J, Blanco-Molina A, Camón AM, Cruz AJ, de Miguel J, del Pozo R, del Toro J, Díaz-Pedroche MC, Díaz-Peromingo JA, Falgá C, Fernández-Aracil C, Fernández-Capitán C, Fernández-Muixi J, Fidalgo MA, Font C, Font L, Furest I, García MA, García-Bragado F, García-Morillo M, García-Raso A, Gavín O, Gaya-Manso I, Gómez C, Gómez V, González J, Grau E, Guijarro R, Gutierrez J, Hernández-Blasco L, Hernando E, Jara-Palomares L, Jara MJ, Jiménez D, Jiménez R, Jiménez S, Joya MD, Lecumberri R, Lima J, Llamas P, Lobo JL, López-Jiménez L, López-Reyes R, López-Sáez JB, Lorente MA, Lorenzo A, Loring M, Madridano O, Maestre A, Manrique-Abos I, Marchena PJ, Martín-Asenjo M, Martín M, Martín-Martos F, Monreal M, Morales MV, Muñoz C, Nieto JA, Nieto S, Núñez MJ, Olivares MC, Otalora S, Otero R, Pedrajas JM, Pellejero G, Pérez-Ductor C, Peris ML, Pons I, Porras JA, Ramírez L, Riera-Mestre A, Rivas A, Rodríguez-Dávila MA, Rosa V, Rubio CM, Ruiz-Artacho P, Sahuquillo JC, Saá-Sainz MC, Samperez A, Sánchez-Martínez R, Sancho T, Soler S, Soto MJ, Suríñach JM, Tolosa C, Torres MI, Trujillo-Santos J, Uresandi F, Usandizaga E, Valero B, Valle R, Vela J, Vidal G, Villalobos A, Xifre B; BELGIUM: Vanassche T, Vandenbroucke C, Verhamme P; BRAZIL: Yoo HHB; CANADA: Wells P; CZECH REPUBLIC: Hirmerova J, Malý R; ECUADOR: del Pozo G, Salgado E, Sánchez GT; FRANCE: Benzidia I, Bertoletti L, Bura-Riviere A, Falvo N, Farge-Bancel D, Hij A, Merah A, Mahé I, Moustafa F, Quere I; ISRAEL: Braester A, Brenner B, Ellis M, Tzoran I; ITALY: Antonucci G, Bilora F, Bertoluzzi C, Brandolin B, Bucherini E, Camerota A, Cattabiani C, Ciaffi-Michelli M, Dentali F, Di Micco P, Duca R, Giorgi-Pierfranceschi M, Grandone E, Imbalzano E, Lessiani G, Maida R, Marampon F, Mastroiacovo D, Pace F, Pesavento R, Poggio R, Prandoni P, Quintavalla R, Rocchi A, Siniscalchi C, Tiraferri E, Tonello D, Visonà A; LATVIA: Gibietis V, Skride A, Vitolia B; REPUBLIC OF MACEDONIA: Zdraveska M; SWITZERLAND: Bounamaque H, Mazzolai I; USA: Caprini JA.

Coordinator of the RIETE Registry: Dr. Manuel Monreal (Spain).

RIETE Steering Committee Members: Dr. Hervé Decousus (France); Dr. Paolo Prandoni (Italy); Dr. Benjamin Brenner (Israel).

RIETE National Coordinators: Dr. Raquel Barba (Spain); Dr. Pierpaolo Di Micco (Italy); Dr. Laurent Bertoletti (France); Dr. Inna Tzoran (Israel); Dr. Abilio Reis (Portugal); Dr. Henri Bounamaque (Switzerland); Dr. Radovan Malý (Czech Republic); Dr. Philip Wells (Canada); Dr. Peter Verhamme (Belgium); Dr. Joseph A. Caprini (USA).

RIETE Registry Coordinating Center: S & H Medical Science Service.